How to Get Dayvigo (Lemborexant) in New Jersey

What Is Dayvigo and Why Would a New Jersey Patient Need It?

Dayvigo (lemborexant) is a dual orexin receptor antagonist approved by the FDA in December 2019 for the treatment of insomnia in adults characterized by difficulty with sleep onset or sleep maintenance. Unlike older sedative-hypnotics such as zolpidem, lemborexant works by blocking wake-promoting orexin neuropeptides rather than broadly depressing central nervous system activity.

In the SUNRISE-1 trial (N=1,006), lemborexant 5 mg and 10 mg significantly reduced latency to persistent sleep compared with placebo at one month. The 10 mg dose cut sleep-onset latency by approximately 10.5 minutes more than placebo, with sustained improvement through six months of treatment [1]. The trial also demonstrated improved sleep efficiency and reduced wake-after-sleep-onset (WASO) time. These data form the clinical basis for prescribing in New Jersey and across the United States.

New Jersey has roughly 9.3 million residents, and national survey data from the CDC's Behavioral Risk Factor Surveillance System show that about 14.5% of U.S. adults report trouble falling asleep most days. That translates to a substantial patient population who may benefit from a targeted insomnia medication. Knowing how to access it within state-specific prescribing and pharmacy regulations saves time.

Step-by-Step: Getting a Dayvigo Prescription in New Jersey

The fastest path from "I can't sleep" to a filled Dayvigo prescription in New Jersey involves three stages: evaluation, prescribing, and pharmacy fulfillment. Each has state-specific details worth knowing.

Stage 1: Clinical evaluation. A licensed prescriber must assess your insomnia symptoms, rule out secondary causes (obstructive sleep apnea, restless legs syndrome, medication-induced insomnia), and confirm that behavioral approaches such as cognitive behavioral therapy for insomnia (CBT-I) have been considered. The American Academy of Sleep Medicine (AASM) recommends CBT-I as first-line therapy, with pharmacotherapy reserved for patients who do not respond or cannot access it [2].

Stage 2: Prescribing. Your provider writes a prescription for lemborexant 5 mg or 10 mg. Because Dayvigo is Schedule IV under the Controlled Substances Act, the prescription must comply with both federal DEA regulations and New Jersey Board of Medical Examiners rules. Electronic prescribing of controlled substances (EPCS) is mandatory in New Jersey as of 2021 under state law P.L.2020, c.108.

Stage 3: Pharmacy fulfillment. The prescription routes to your chosen retail, mail-order, or 503A compounding pharmacy. Retail chains (CVS, Walgreens, Rite Aid) across all 21 New Jersey counties stock Dayvigo. Specialty or 503A pharmacies offer an alternative for patients who need compounded formulations, though the standard Eisai-manufactured tablet is the most common dispensing route.

Most patients complete all three stages within 3 to 5 business days. Telehealth can compress Stage 1 and Stage 2 into a single day.

Telehealth Prescribing of Dayvigo in New Jersey

New Jersey permits telehealth prescribing of Schedule IV controlled substances, making Dayvigo accessible without an in-person office visit. This is a significant advantage for patients in rural southern New Jersey counties or those with mobility limitations.

Under the New Jersey Telemedicine Act (P.L.2017, c.117), a provider-patient relationship can be established via live audio-video consultation. The prescribing clinician must hold an active New Jersey medical license (or equivalent for NPs and PAs). A telephone-only visit does not satisfy the requirement for initial controlled substance prescribing; video is mandatory for the first encounter.

After the initial video evaluation, follow-up visits may use audio-only communication at the provider's discretion. The prescriber sends the electronic prescription directly to the patient's selected New Jersey pharmacy. No separate paper prescription is needed.

Several telehealth-forward sleep medicine practices operate in New Jersey. When selecting a provider, verify three things: active NJ licensure, DEA registration with a New Jersey address, and EPCS capability. These three checks prevent delays at the pharmacy counter.

Who Can Prescribe Dayvigo in New Jersey: MD, NP, and PA Scope

Three categories of prescriber can write a Dayvigo prescription in New Jersey. The details differ for each.

Physicians (MD/DO): Any physician with an active New Jersey medical license and a current DEA registration may prescribe lemborexant. No additional sleep medicine board certification is required, though many prescriptions originate from primary care, psychiatry, or sleep medicine specialists.

Nurse practitioners (NP): New Jersey grants NPs full practice authority under P.L.2018, c.56 after a supervised practice period. An NP who has completed the collaborative period and holds a CDS (Controlled Dangerous Substance) registration can independently prescribe Schedule IV medications, including Dayvigo. NPs still in their collaborative period need a joint protocol with a collaborating physician.

Physician assistants (PA): PAs in New Jersey prescribe under a practice agreement with a supervising physician. The agreement must specifically authorize Schedule IV prescribing. A PA with appropriate authorization and a CDS registration may prescribe lemborexant.

Bottom line: if your provider holds an active NJ license and a CDS/DEA registration for Schedule IV drugs, the prescription is valid regardless of whether they are an MD, DO, NP, or PA.

Insurance and Prior Authorization in New Jersey

Cost is the single most common barrier to Dayvigo access. The brand-name tablet carries a retail cash price often exceeding $400 for a 30-day supply. Insurance coverage softens that number, but the path varies by plan type.

New Jersey Medicaid (NJ FamilyCare): Medicaid covers Dayvigo with prior authorization (PA). The PA process typically requires documentation that the patient has tried and failed (or has a contraindication to) at least one generic sleep agent, commonly zolpidem or trazodone. The prescriber's office submits the PA request to the Medicaid managed care organization. Turnaround is usually 48 to 72 hours, though urgent requests may be processed within 24 hours.

Commercial insurance: Coverage depends on the specific formulary. Many commercial plans in New Jersey place Dayvigo on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Step therapy requirements are common: insurers often require prior trials of generic zolpidem, suvorexant, or trazodone before authorizing Dayvigo. A 2023 analysis in the American Journal of Managed Care found that step therapy for branded insomnia agents delayed time-to-fill by a median of 11 days [3].

Medicare Part D: Dayvigo appears on many Part D formulary lists, but tier placement and copay vary by plan. The Medicare Plan Finder can identify which Part D plans in New Jersey cover lemborexant and at what cost-sharing level.

Eisai copay assistance: Eisai offers a copay card for commercially insured patients that may reduce out-of-pocket costs to as low as $0 to $30 per month. This program does not apply to government-funded insurance (Medicaid, Medicare, Tricare).

What Documentation Does Prior Authorization Require?

A successful PA submission in New Jersey generally requires four elements packed into a single clinical narrative.

First, the prescriber documents the insomnia diagnosis with ICD-10 code G47.00 (insomnia, unspecified) or G47.01 (insomnia due to medical condition), along with symptom duration. Most insurers expect symptoms persisting at least three months. Second, the submission lists prior pharmacologic trials, including drug name, dose, duration, and reason for discontinuation (lack of efficacy, adverse effects, or both). Third, a clinical rationale explains why lemborexant is appropriate. This is where citing the DORA mechanism and its differentiated safety profile relative to benzodiazepine receptor agonists strengthens the request. A 2020 meta-analysis published in the Lancet comparing 30 insomnia medications found that lemborexant had a favorable balance of efficacy and next-day residual effects compared with older Z-drugs [4]. Fourth, some plans require documentation that non-pharmacologic therapy (CBT-I) was offered or attempted.

Submitting all four components upfront reduces the rate of initial PA denial. If a PA is denied, New Jersey patients have appeal rights under NJAC 11:24A, and the prescriber can file a peer-to-peer review with the plan's medical director.

Labs and Assessments Before Starting Dayvigo

Lemborexant does not require routine laboratory monitoring before initiation or during treatment. No hepatic panel, renal function tests, or drug levels are mandated by the FDA label. This contrasts with certain other sleep medications and makes the prescribing pathway faster.

However, a thorough clinical assessment should occur before the first prescription. The AASM clinical practice guideline recommends screening for obstructive sleep apnea (OSA) using a validated questionnaire such as STOP-Bang, because orexin antagonists do not treat and could theoretically mask OSA symptoms [2]. Patients with a STOP-Bang score of 5 or higher, or with symptoms like witnessed apneas and excessive daytime sleepiness, may benefit from a home sleep apnea test before starting any hypnotic.

A medication reconciliation is also critical. Lemborexant is metabolized primarily by CYP3A4. Co-administration with strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) is contraindicated per the FDA label, and moderate CYP3A4 inhibitors require dose reduction to 5 mg [5]. Your provider should review your current medications for CYP3A4 interactions before writing the prescription.

New Jersey Pharmacy Options: Retail, Mail-Order, and 503A

Once the prescription clears, patients choose a dispensing pharmacy. New Jersey offers all three major channels.

Retail pharmacies: CVS, Walgreens, Rite Aid, and independent pharmacies across the state stock or can order Dayvigo. Most retail pharmacies receive the product from wholesale distributors within one business day if not already on shelf. Because lemborexant is Schedule IV, it must be stored in a locked cabinet or secured area per NJ pharmacy board regulation N.J.A.C. 13:39-9.17.

Mail-order pharmacies: For patients with commercial insurance or Medicare Part D, mail-order options (Express Scripts, CVS Caremark, OptumRx) typically offer a 90-day supply at a lower per-unit cost. Shipping to any New Jersey address is standard. Expect 5 to 7 business days for the first fill and 3 to 5 business days for refills.

503A compounding pharmacies: New Jersey licenses 503A compounding pharmacies under the State Board of Pharmacy. These pharmacies can compound patient-specific prescriptions when a clinical need exists (for example, a patient who cannot swallow tablets might need a liquid formulation). However, 503A pharmacies compound from bulk drug substances and are not interchangeable with commercially manufactured Dayvigo unless the prescriber documents a medical need for an alternative dosage form. A 503A pharmacy may not ship compounded lemborexant across state lines to a New Jersey patient unless it also holds a 503B outsourcing facility registration.

Transferring a Dayvigo Prescription to New Jersey

Patients relocating to New Jersey or visiting from another state can transfer an existing Dayvigo prescription under specific conditions.

New Jersey permits the transfer of Schedule IV prescriptions between pharmacies, including across state lines, provided the prescription has remaining refills. The receiving New Jersey pharmacy contacts the originating pharmacy to verify and transfer the prescription record. Under federal regulation 21 CFR 1306.26, a Schedule III-V prescription may be transferred once between pharmacies unless both are in a shared real-time database (as with chain pharmacies sharing the same system), in which case multiple transfers are permitted.

If the prescription has no remaining refills, a new prescription from a New Jersey-licensed provider is required. A telehealth visit with a New Jersey provider is the fastest path here. The new provider can access out-of-state medical records with patient consent and issue a fresh electronic prescription to a New Jersey pharmacy.

Patients should also confirm that their insurance plan covers prescriptions filled in New Jersey. Most national plans have statewide pharmacy networks, but narrow-network plans may limit which pharmacies accept the coverage.

Dosing and Safety: What New Jersey Patients Should Know

The FDA-approved dosing is straightforward. The recommended starting dose is 5 mg taken orally once per night, within 30 minutes of going to bed, with at least 7 hours of intended sleep remaining. The dose may be increased to 10 mg if the 5 mg dose is well tolerated but insufficiently effective [5].

In the SUNRISE-2 trial (N=949), which studied lemborexant over 12 months, the most common adverse events were somnolence (10% at 10 mg vs. 1% placebo), headache (6% vs. 4%), and fatigue (3% vs. 1%) [6]. According to data published in Sleep Medicine, no evidence of physical dependence or rebound insomnia emerged after abrupt discontinuation at 12 months, a finding that differentiates DORAs from benzodiazepine receptor agonists [6].

Alcohol should be avoided. Combining lemborexant with CNS depressants amplifies sedation. Patients should not drive or operate heavy machinery until they know how the drug affects them. The FDA label includes a warning about sleep-related complex behaviors (sleepwalking, sleep-driving), though the incidence in clinical trials was low (under 1%).

For patients taking moderate CYP3A4 inhibitors such as fluconazole or verapamil, the maximum recommended dose is 5 mg. Strong CYP3A4 inducers (rifampin, carbamazepine, St. John's wort) may reduce lemborexant efficacy by increasing its clearance [5].